Dr Ruth Griffin

Vaccine development against infectious bacteria. Current R&D is focused on Clostridium difficile. Preclinical trials planned for September 2018.

 

Research into the vaccine antigen (FHbp) of two recently licensed serogroup B meningococcal vaccines has found a problem with this antigen that will result in over 20% of strains to escape targeting by one of these vaccines. 

Ruth is interested in external consultancy and research collaboration opportunities.

Staff webpage